Mirzaei Reza, Gordon Ashley, Zemp Franz J, Kumar Mehul, Sarkar Susobhan, Luchman H Artee, Bellail Anita C, Hao Chunhai, Mahoney Douglas J, Dunn Jeff F, Bose Pinaki, Yong V Wee
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
Sci Adv. 2021 Nov 5;7(45):eabh2148. doi: 10.1126/sciadv.abh2148.
Brain tumor–initiating cells (BTICs) drive glioblastoma growth through not fully understood mechanisms. Here, we found that about 8% of cells within the human glioblastoma microenvironment coexpress programmed cell death 1 (PD-1) and BTIC marker. Gain- or loss-of-function studies revealed that tumor-intrinsic PD-1 promoted proliferation and self-renewal of BTICs. Phosphorylation of tyrosines within the cytoplasmic tail of PD-1 recruited Src homology 2–containing phosphatase 2 and activated the nuclear factor kB in BTICs. Notably, the tumor-intrinsic promoting effects of PD-1 did not require programmed cell death ligand 1(PD-L1) ligation; thus, the therapeutic antibodies inhibiting PD-1/PD-L1 interaction could not overcome the growth advantage of PD-1 in BTICs. Last, BTIC-intrinsic PD-1 accelerated intracranial tumor growth, and this occurred in mice lacking T and B cells. These findings point to a critical role for PD-1 in BTICs and uncover a nonimmune resistance mechanism of patients with glioblastoma to PD-1– or PD-L1–blocking therapies.
脑肿瘤起始细胞(BTICs)通过尚未完全明确的机制驱动胶质母细胞瘤生长。在此,我们发现人类胶质母细胞瘤微环境中约8%的细胞共表达程序性细胞死亡蛋白1(PD-1)和BTIC标志物。功能获得或丧失研究表明,肿瘤内在的PD-1促进了BTICs的增殖和自我更新。PD-1胞质尾部酪氨酸的磷酸化招募含Src同源2结构域的磷酸酶2,并激活BTICs中的核因子κB。值得注意的是,PD-1的肿瘤内在促进作用并不需要程序性细胞死亡配体1(PD-L1)的结合;因此,抑制PD-1/PD-L1相互作用的治疗性抗体无法克服PD-1在BTICs中的生长优势。最后,BTIC内在的PD-1加速了颅内肿瘤生长,且这种情况发生在缺乏T细胞和B细胞的小鼠中。这些发现表明PD-1在BTICs中起关键作用,并揭示了胶质母细胞瘤患者对PD-1或PD-L1阻断疗法的非免疫抵抗机制。